Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells

Journal of Medical Investigation

Volumn 52, Issue 1-2, 2005, Pages 1-9

  Nomura, Toshiyuki ^a   Katunuma, Nobuhiko ^b  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b TOKUSHIMA BUNRI UNIVERSITY   (Japan)

Author keywords

Cancer; Cathepsins; Inhibitors; Invasion; Metastasis

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN; CATHEPSIN B; CATHEPSIN D; CATHEPSIN L; CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; LYSOSOME ENZYME; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 4; PROTEIN INHIBITOR; PROTEINASE; RANTES; STROMAL CELL DERIVED FACTOR 1; UNINDEXED DRUG; COMPLEMENTARY DNA; CYSTEINE PROTEINASE INHIBITOR;

ANIMAL CELL; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER THERAPY; CELL FUNCTION; CELL INVASION; CELL PROLIFERATION; DEGRADATION; DENDRITIC CELL; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MITOGENESIS; MOUSE; NONHUMAN; PROGNOSIS; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; REVIEW; STOMACH CANCER; TUMOR IMMUNITY; ANIMAL; ENZYMOLOGY; GENETICS; NEOPLASM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; CATHEPSINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTEINE PROTEINASE INHIBITORS; DNA, ANTISENSE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS;

EID: 15544384612     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: 10.2152/jmi.52.1     Document Type: Review

References (63)

1. Liotta LA, Rao CN, Wewer UM: Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 55: 1037-1035, 1986
2. Woodhouse EC, Chuaqui RF, Liotta LA: General mechanisms of metastasis. Cancer 80: 1529-1537, 1997
3. Kos J, Lah TT: Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Oncol Rep 5: 1349-1346, 1998
4. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WL, Klijn JG: Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 79: 300-307, 1999
5. Lah TT, Cercek M, Blejec A, Kos J, Gorodetsky E, Somers R, Daskal I: Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators. Clin Cancer Res 6: 578-584, 2000
6. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M, Hanahan D: Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5: 443-453, 2004
7. Gabel CA, Goldberg DE, Kornfeld S: Identification and characterization of cells deficient in the mannose 6-phosphate receptor: evidence for an alternate pathway for lysosomal enzyme targeting. Proc Natl Acad Sci USA 80: 775-779, 1983
8. Rochefort H: Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer 28A: 1780-1783, 1992
9. Ferrandina G, Scambia G, Bardelli F, Benedetti Panici P, Mancuso S, Messori A: Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer 76: 661-666, 1997
10. Cherry JP, Mordente JA, Chapman JR, Choudhury MS, Tazaki H, Mallouh C, Konno S: Analysis of cathepsin D forms and their clinical implications in human prostate cancer. J Urol 160 (6 Pt 1): 2223-2228, 1998
11. Rochefort H, Cavailles V, Augereau P, Capony F, Maudelonde T, Touitou I, Garcia M: Overexpression and hormonal regulation of pro-cathepsin D in mammary and endometrial cancer. J Steroid Biochem 34: 177-182, 1989
12. Cavailles V, Augereau P, Rochefort H: Cathepsin D gene is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in breast cancer cells. Proc Natl Acad Sci USA 90: 203-207, 1993
13. Sloane BF, Rozhin J, Hatfield JS, Crissman JD, Honn KV: Plasma membrane-associated cysteine proteinases in human and animal tumors. Exp Cell Biol 55: 209-224, 1987
14. Denhardt DT, Greenberg AH, Egan SE, Hamilton RT, Wright JA: Cysteine proteinase cathepsin L expression correlates closely with the metastatic potential of H-ras-transformed murine fibroblasts. Oncogene 2: 55-59, 1987
15. Qian F, Bajkowski AS, Steiner DF, Chan SJ, Frankfeter A: Expression of five cathepsins in murine melanomas of varying metastatic potential and normal tissues. Cancer Res 49: 4870-4875, 1989
16. Katunuma N, Tsuge H, Nukatsuka M, Asao T, Fukushima M: Structure-based design of specific cathepsin inhibitors and their application to protection of bone metastases of cancer cells. Arch Biochem Biophys 397: 305-311, 2002
17. Vetvicka V, Vetvickova J, Fusek M: Anti-human procathepsin D activation peptide antibodies inhibit breast cancer development Breast Cancer Res Treat 57: 261-269, 1999
18. Fusek M and Vetvicka V: Mitogenic function of human procathepsin D: the role of the propeptide. Biochem J 303(Pt 3): 775-780, 1994
19. Glondu M, Liaudet-Coopman E, Derocq D, Platet N, Rochefort H, Garcia M: Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene 21: 5127-5134, 2002
20. Berchem G, Glondu M, Gleizes M, Brouillet JP, Vignon F, Garcia M, Liaudet-Coopman E: Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 21: 5951-5955, 2002
21. Glondu M, Coopman P, Laurent-Matha V, Garcia M, Rochefort H, Liaudet-Coopman E: A mutated cathepsin-D devoid of its catalytic activity stimulates the growth of cancer cells. Oncogene 20: 6920-6929, 2001
22. Wolf M, Clark-Lewis I, Buri C, Langen H, Lis M, Mazzucchelli L: Cathepsin D specifically cleaves the chemokines macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-1 beta, and SLC that are expressed in human breast cancer. Am J Pathol 162: 1183-1190, 2003
23. Griffiths JR: Are cancer cells acidic? Br J Cancer 64: 425-427, 1991
24. Montcourrier P, Silver I, Farnoud R, Bird I, Rochefort H: Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin Exp Metastasis 15: 382-392, 1997
25. Kubota S, Seyama Y: Overexpression of vacuolar ATPase 16-kDa subunit in 10T1/2 fibroblasts enhances invasion with concomitant induction of matrix metalloproteinase-2. Biochem Biophys Res Commun 278: 390-394, 2000
26. +-ATPase in Human Breast Cancer Cells with Distinct Metastatic Potential: Distribution and Functional Activity. Am J Physiol Cell Physiol 286: C1443-1452, 2004
27. Homey B, Muller A, Zlotnik A: Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2: 175-184, 2002
28. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, Qin S, Lanzavecchia A: Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 28: 2760-2769, 1998
29. Sozzani S, Allavena P, Vecchi A, Mantovani A: Chemokines and dendritic cell traffic. J Clin Immunol 20: 151-160, 2000
30. Vicari AP, Caux C, Trinchieri G: Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 12: 33-42, 2002
31. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I, Ben-Baruch A: Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 59: 4681-4687, 1999
32. Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M: Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92: 1085-1091, 2001
33. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6: 3282-3289, 2000
34. De Larco JE, Wuertz BR, Rosner KA, Erickson SA, Gamache DE, Manivel JC, Furcht LT: A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol 158: 639-649, 2001
35. Fernandis AZ, Prasad A, Band H, Klosel R, Ganju RK: Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 23: 157-167, 2004
36. Lah TT, Kos J, Blejec A, Frkovic-Georgio S, Golouh R, Vrhovec I, Turk V: The Expression of Lysosomal Proteinases and Their Inhibitors in Breast Cancer: Possible Relationship to Prognosis of the Disease. Pathol Oncol Res 3: 89-99, 1997
37. Levicar N, Kos J, Blejec A, Golouh R, Vrhovec I, Frkovic-Grazio S, Lah TT: Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients. Cancer Detect Prev 26: 42-49, 2002
38. Friedrich B, Jung K, Lein M, Turk I, Rudolph B, Hampel G, Schnorr D, Loening SA: Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue. Eur J Cancer 35: 138-144, 1999
39. Dohchin A, Suzuki JI, Seki H, Masutani M, Shiroto H, Kawakami Y: Immunostained cathepsins B and L correlate with depth of invasion and different metastatic pathways in early stage gastric carcinoma. Cancer 89: 482-487, 2000
40. Thomssen C, Oppelt P, Janicke F, Ulm K, Harbeck N, Hofler H, Kuhn W, Graeff H, Schmitt M: Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. Anticancer Res 18: 2173-2180, 1998
41. Foekens JA, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N, Meijer-van Gelder ME, Henzen-Logmans, SC, van Putten, WL, Klijn, JG: Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol 16: 1013-1021, 1998
42. Zajc I, Sever N, Bervar A, Lah TT: Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines. Cancer Lett 187: 185-190, 2002
43. Schwartz MK: Tissue cathepsins as tumor markers. Clin Chim Acta 237: 67-78, 1995
44. Colella R, Goodwyn E, Gopal P: Increased cell density decreases cysteine proteinase inhibitor activity and increases invasive ability of two prostate tumor cell lines. Cancer Lett 185: 163-172, 2002
45. Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL, Gleason DF: Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma. Cancer 94: 3141-3149, 2002
46. Colella R, Casey SF: Decreased activity of cathepsins L+B and decreased invasive ability of PC3 prostate cancer cells. Biotech Histochem 78: 101-108, 2003
47. Mohanam S, Jasti SL, Kondraganti SR, Chandrasekar N, Lakka SS, Kin Y, Fuller GN, Yung AW, Kyritsis AP, Dinh DH, Olivero WC, Gujrati M, Ali-Osman F, Rao JS: Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 20: 3665-3673, 2001
48. Szpaderska AM, Frankfater A: An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 61: 3493-3500, 2001
49. Kirschke H, Eerola R, Hopsu-Havu VK, Bromme D, Vuorio E: Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells. Eur J Cancer 36: 787-795, 2000
50. Premzl A, Puizdar V, Zavasnik-Bergant V, Kopitar-Jerala N, Lah TT, Katunuma N, Sloane BF, Turk V, Kos J: Invasion of ras-transformed breast epithelial cells depends on the proteotytic activity of cysteine and aspartic proteinases. Biol Chem 382: 853-857, 2001
51. Saegusa K, Ishimaru N, Yanagi K, Arakaki R, Ogawa K, Saito I, Katunuma N, Hayashi Y: Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest 110: 361-369, 2002
52. Murata M, Miyashita S, Yokoo C, Tamai M, Hanada K, Hatayama K, Towatari T, Nikawa T, Katunuma N: Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. FEBS Lett 280: 307-310, 1991
53. Towatari T, Nikawa T, Murata M, Yokoo C, Tamai M, Hanada K, Katunuma N: Novel epoxysuccinyl peptides. A selective inhibitor of cathepsin B, in vivo. FEBS Lett 280: 311-315, 1991
54. Katunuma N and Kominami E: Structure, Properties, Mechanisms, and Assays of Cysteine Protease inhibitors; Cystatins and E-64 Derivatives. Methods in Enzymology 251: 382-397, 1995
55. Katunuma N, Murata E, Kakegawa H, Matsui A, Tsuzuki H, Tsuge H, Turk D, Turk V, Fukushima M, Tada Y, Asao T: Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo. FEBS Lett 458: 6-10, 1999
56. Yasuma T, Oi S, Choh N, Nomura T, Furuyama N, Nishimura A, Fujisawa Y, Sohda T: Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption. J Med Chem 41: 4301-4308, 1998
57. Buttle DJ, Murata M, Knight CG, Barrett AJ: CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch Biochem Biophys 299: 377-380, 1992
58. Bervar A, Zajc I, Sever N, Katunuma N, Sloane BF, Lah TT: Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors. Biol Chem 384: 447-455, 2003
59. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ: Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 6: 1038-1045, 2000
60. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ: Metastatic patterns of prostate cancer: an autopsy study of 1, 589 patients. Hum Pathol 31: 578-583, 2000
61. Meara JP, Rich DH: Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors. J Med Chem 39: 3357-3366, 1996
62. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295(5564): 2387-2392 (Review), 2002
63. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392: 190-193, 1998